David Denofrio, MD
Advanced Heart Failure and Transplant Cardiology · Boston, MANPI 1679679997
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,630 of the $17,898 with a category attached, or 92.9%. Biocardia, Inc. accounts for 64.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $5,800 and has fallen 92.7% since, to $422 in 2025.
Across 25 payments — averaging $715.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biocardia, Inc.$12K
- Vifor Pharma, Inc.$3K
- Amgen$2K
- Cvrx, Inc.$530
- Abbott$368
- Pfizer$248
- plus $80 from 2 others
What the payments were for
- Consulting fees$16,63093%
- Food & beverage$1,2687%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biocardia, Inc. | 2 | $11,500 |
| Vifor Pharma, Inc. | 3 | $2,791 |
| Amgen | 1 | $2,380 |
| Cvrx, Inc. | 5 | $530 |
| Abbott | 4 | $368 |
| Pfizer | 8 | $248 |
| La Jolla Pharmaceutical Company | 1 | $50 |
| Boehringer Ingelheim | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$2,750
- Corlanor$2,380
- Barostim Neo System$391
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$304
How this compares
$17,898 in reported general payments places this provider in the 70th percentile of 35 advanced heart failure and transplant cardiology providers in Massachusetts.
See all advanced heart failure and transplant cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 95 | $128,665 |
| FarxigaDapagliflozin Propanediol | 72 | $64,405 |
| EliquisApixaban | 27 | $42,108 |
| JardianceEmpagliflozin | 21 | $23,946 |
| Repatha SureclickEvolocumab | 37 | $21,086 |
| VascepaIcosapent Ethyl | 23 | $10,682 |
| OzempicSemaglutide | 11 | $10,322 |
| Tacrolimus | 47 | $9,704 |
| Mycophenolate Mofetil | 49 | $2,491 |
| GengrafCyclosporine, Modified | 13 | $2,432 |
| Torsemide | 67 | $1,869 |
| Metoprolol Succinate | 99 | $1,798 |
| Potassium Chloride | 33 | $1,506 |
| Ranolazine ErRanolazine | 17 | $1,397 |
| Bumetanide | 31 | $1,172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $248 | $42,10827 claims |
| Boehringer IngelheimJardiance | $30 | $23,94621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 35 advanced heart failure and transplant cardiology providers in Massachusetts.
Other advanced heart failure and transplant cardiology in Boston
- Pablo Quintero PinzonBoston$137K
- Daniel ZlotoffBoston$96K
- Christina Vander PluymBoston$55K
- Monica AhluwaliaBoston$39K
- Stephanie MooreBoston$30K
- Robb KociolBoston$12K
- Marwa SabeBoston$12K
- Edward GrandinBoston$8K
- Kemar BrownBoston$7K
- Kevin DalyBoston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.